Banister, SD; Connor, M. The chemistry and pharmacology of synthetic cannabinoid receptor agonist new psychoactive substances: Evolution In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 191-226. 1.2 MB. https://doi.org/10.1007/164_2018_144 #107
Brandt, SD; Kavanagh, PV; Westphal, F; Dreiseitel, W; Dowling, G; Bowden, MJ; Williamson, JPB. Synthetic cannabinoid receptor agonists: Analytical profiles and development of QMPSB, QMMSB, QMPCB, 2F-QMPSB, QMiPSB, and SGT-233 Drug Test. Anal., 16 Aug 2020, 13 (1), 175-196. 2.6 MB. https://doi.org/10.1002/dta.2913 #1 GC,MS,NMR
Richter, MJ; Wagmann, L; Gampfer, TM; Brandt, SD; Meyer, MR. In vitro metabolic fate of the synthetic cannabinoid receptor agonists QMPSB and QMPCB (SGT-11) including isozyme mapping and esterase activity Metabolites, 1 Aug 2021, 11 (8), 509. 3.3 MB. https://doi.org/10.3390/metabo11080509 #QMPSB MS
Richter, MJ; Wagmann, L; Kavanagh, PV; Brandt, SD; Meyer, MR. In vitro metabolic fate of the synthetic cannabinoid receptor agonists (quinolin‐8‐yl 4‐methyl‐3‐(morpholine‐4‐sulfonyl)benzoate [QMMSB]) and (quinolin‐8‐yl 4‐methyl‐3‐((propan‐2‐yl)sulfamoyl)benzoate [QMiPSB]) including isozyme mapping and carboxylesterases activity testing Drug Test. Anal., 26 Oct 2022. 2.2 MB. https://doi.org/10.1002/dta.3385 #QMPSB MS
Lambeng, N; Lebon, F; Christophe, B; Burton, M; De Ryck, M; Quéré, L. Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: Identification of a lead and initial SAR studies Bioorg. Med. Chem. Lett., 1 Jan 2007, 17 (1), 272–277. 247 kB. https://doi.org/10.1016/j.bmcl.2006.09.049 #1